15 June 2026 / CBD regulation
CBD novel foods after the UK-EU reset: what businesses should watch
For CBD manufacturers and retailers, the risk is not an overnight ban. The harder question is whether GB applications, EU authorisation and evidence requirements start to converge before every business gets the clarity it hoped for.
Industry view
The reset does not change CBD overnight. It changes the planning horizon.
As of June 2026, the GB CBD novel food process remains active. The FSA has said domestic rules continue until any UK-EU SPS agreement is implemented.
The commercial uncertainty is route timing. If dynamic alignment brings regulated food authorisations into the EU route, some CBD operators may still be mid-process in Great Britain when the practical market-access path changes.
Route certainty
CBD is caught in a wider food-law reset.
The proposed UK-EU SPS agreement is not a CBD-only measure. It is a food and feed safety alignment programme, and the FSA has said regulated product authorisations are part of the work being examined.
That matters because CBD is already a regulated product category waiting on authorisation decisions. A wider route change can still create a CBD-specific commercial problem if applications, retailer policies and product evidence do not move at the same speed.
- Scope
- Regulated food and feed products are in the SPS discussion
- Timing
- Implementation planning points toward mid-2027
- Unknown
- Transition rules, exceptions and application handling
What listing means
The public list is useful, but it is not market certainty.
FSA public list
The list identifies CBD food products linked to applications that met the route criteria for remaining on sale while assessment continues.
Novel food authorisation
Authorisation is the later safety and decision stage. Validation, or progress toward validation, does not guarantee that a product will be authorised.
For retailers, this distinction matters: a listing is a due-diligence signal, not an endorsement, approval or substitute for checking labels, claims and batch evidence.
EFSA 2026
The EU signal makes evidence discipline harder to avoid.
In February 2026, EFSA set a provisional adult intake level of 0.0275mg per kg bodyweight per day for a defined high-purity CBD supplement case. For a 70kg adult, EFSA described that as about 2mg per day.
That is not a blanket approval for the CBD market. EFSA also flagged data gaps and said the provisional level does not cover under-25s, pregnancy, breastfeeding or people taking medication.
- Provisional level
- 0.0275mg/kg bw/day for the defined adult supplement case
- Not covered
- Under-25s, pregnancy, breastfeeding and medication use
- Business meaning
- Generic wellness claims will not replace formulation-level evidence
What to do now
The sensible move is to make evidence travel across routes.
Waiting for the final legal architecture is not the same as standing still. Brands need to know their application status, understand where EU evidence expectations may bite, and keep retailer-facing records ready to inspect.
Retailers have a parallel problem. "On the list" is useful, but it does not replace label checks, batch records, ingredient clarity, responsible claims and controlled-cannabinoid controls.
Industry questions
The hard questions are commercial as much as regulatory.
Does the EU reset make CBD illegal in the UK now?
No. The reset does not make CBD illegal by itself. Current domestic rules continue until any agreement is implemented, and ingestible CBD remains a novel food category in Great Britain.
Does the FSA CBD list mean a product is approved?
No. The FSA says the public list is not an authorisation list. It identifies products linked to applications that met the relevant route criteria while assessment continues.
Should brands abandon the FSA route and focus on the EU?
Not automatically. The FSA has said businesses will need to decide whether to continue through the GB process or focus on the EU route while exceptions and transition details remain unconfirmed.
Where the advantage sits
The safer commercial position is evidence before volume.
If the route changes, the businesses with cleaner records will be easier to trust. That means batch testing, sober consumer advice, traceable manufacturing, current source references and labels that explain the product without pretending it is a medicine.
- Manufacturer check
- Application route, formulation evidence and source-backed records
- Retailer check
- List status, labels, batch evidence and claims discipline
- Consumer-facing check
- Clear warnings, responsible servings and accessible lab evidence